Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd R Burmester

Showing results (211-220 of 293) with videos related to

Pageof 30
Sort By:
Clinical and Experimental Rheumatology|March 12, 2016
Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Rheumatology and Therapy|October 9, 2022
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 StudyBernard G Combe, Yoshiya Tanaka, Maya H Buch, et al.
RMD Open|February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitisGerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
Therapeutic Advances in Musculoskeletal Disease|August 25, 2022
Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional studyJulia Schally, Henning Christian Brandt, Jan Brandt-Jürgens, et al.
Annals of the Rheumatic Diseases|March 17, 2017
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritisSofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, et al.
Annals of the Rheumatic Diseases|December 24, 2016
Low immunogenicity of tocilizumab in patients with rheumatoid arthritisGerd R Burmester, Ernest Choy, Alan Kivitz, et al.
RMD Open|February 18, 2022
SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathiesManuel Graf, Sae Lim von Stuckrad, Akinori Uruha, et al.
Annals of the Rheumatic Diseases|March 12, 2013
Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment responsePhilipp Enghard, Claudia Rieder, Katharina Kopetschke, et al.
Arthritis and Rheumatism|February 24, 2010
Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluidHans U Scherer, Diane van der Woude, Andreea Ioan-Facsinay, et al.
Annals of the Rheumatic Diseases|June 1, 2010
Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosisLijana Krause, Mike O Becker, Claudia S Brueckner, et al.
Pageof 30

Showing results (211-220 of 293) with videos related to

Sort By:
Pageof 30
Clinical and Experimental Rheumatology|March 12, 2016
Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Rheumatology and Therapy|October 9, 2022
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 StudyBernard G Combe, Yoshiya Tanaka, Maya H Buch, et al.
RMD Open|February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitisGerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
Therapeutic Advances in Musculoskeletal Disease|August 25, 2022
Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional studyJulia Schally, Henning Christian Brandt, Jan Brandt-Jürgens, et al.
Annals of the Rheumatic Diseases|March 17, 2017
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritisSofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, et al.
Annals of the Rheumatic Diseases|December 24, 2016
Low immunogenicity of tocilizumab in patients with rheumatoid arthritisGerd R Burmester, Ernest Choy, Alan Kivitz, et al.
RMD Open|February 18, 2022
SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathiesManuel Graf, Sae Lim von Stuckrad, Akinori Uruha, et al.
Annals of the Rheumatic Diseases|March 12, 2013
Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment responsePhilipp Enghard, Claudia Rieder, Katharina Kopetschke, et al.
Arthritis and Rheumatism|February 24, 2010
Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluidHans U Scherer, Diane van der Woude, Andreea Ioan-Facsinay, et al.
Annals of the Rheumatic Diseases|June 1, 2010
Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosisLijana Krause, Mike O Becker, Claudia S Brueckner, et al.
Pageof 30